The present invention relates to an antibody-drug conjugate (ADC) comprising: (a) Brentuximab, wherein Brentuximab comprises at the C-terminus of the light chains, the heavy chains or all of the heavy and light chains of the Brentuximab a recognition sequence for tubulin tyrosine ligase and a non-natural amino acid; and (b) at least one drug moiety; wherein a drug moiety is coupled to each of the non-natural amino acids via a linker. The present invention further relates to methods of producing same, pharmaceutical compositions comprising same as well as uses thereof.
本发明涉及一种
抗体药物偶联物(ADC),包括:(a)Brentuximab,其中Brentuximab在轻链、重链或所有重链和轻链的C-末端具有识别微管蛋白
酪氨酸连接酶的识别序列和非天然
氨基酸;以及(b)至少一种药物基团;其中每个药物基团通过连接剂连接到每个非天然
氨基酸上。本发明还涉及制备该ADC的方法、包含该ADC的制药组合物以及其用途。